Clinical trialPhase 3Completed
Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer
Clinical Efficacy of QingyiHuaji Optimized Formula Combined With Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer: a Prospective, Multicenter, Randomized Controlled Clinical Study
- Outcome
- Finished, no results posted
- Phase
- Phase 3
- Status
- Completed
- Study type
- Interventional
- Start
- 17 April 2023
- Expected end
- 30 December 2025
- Enrollment
- 305 participants
- Sites
- 4
- Primary outcomes
- Overall survival (OS)
- Sponsor
- Other
- Results posted
- No
- Last update
- 3 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 5
- BackgroundRadiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy. DOI 10.1016/j.pan.2017.08.072↗
- BackgroundPancreatic cancer. DOI 10.1016/s0140-6736(16)00141-0↗
- BackgroundGemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. DOI 10.1200/jco.2011.36.5742↗
- BackgroundFOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. DOI 10.1056/nejmoa1011923↗
- BackgroundMultimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chines… DOI 10.1097/mpa.0b013e3181e6e398↗